Rituximab has emerged as a significant player in the treatment landscape for different autoimmune diseases and particular types of cancer. As a targeted antibody specifically focusing on CD20 proteins on the surface of B cells, rituximab presents a new approach compared to conventional therapies that often employ broader mechanisms of
